<DOC>
	<DOCNO>NCT00917306</DOCNO>
	<brief_summary>The open label study design ass safety efficacy 0.05 % PEP005 Gel apply area skin contain 4-8 AK lesion non-head location .</brief_summary>
	<brief_title>A Multi-center Study Evaluate Safety Efficacy PEP005 ( Ingenol Mebutate ) Gel , When Used Treat Actinic Keratoses Non-head Locations ( Trunk Extremities )</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Patient male female least 18 year age . Female patient must either : Nonchildbearing potential , postmenopausal , confirm clinical history sterility ( e.g. , patient without uterus ) Childbearing potential , provide negative urine pregnancy test result prior study treatment , rule pregnancy Exclusion Criteria Cosmetic therapeutic procedure within two week within 2 cm select treatment area . Treatment immunomodulators , interferon/ interferon inducer systemic medication suppress immune system within 4 week . Treatment 5FU , imiquimod , diclofenac , photodynamic therapy : within 8 week 2 cm select treatment area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>